Omaxe raises Rs 500 crore from Oaktree as growth capital
Omaxe
has raised Rs 500 crore from funds managed by
Oaktree Capital Management
, a global investment managers specializing in alternative investments.
In January 2024, the builder had raised Rs 450 crore from
Kotak Mahindra Bank
Limited.
Explore courses from Top Institutes in
Please select course:
Select a Course Category
Leadership
healthcare
MCA
others
Product Management
Cybersecurity
Operations Management
Degree
Digital Marketing
Finance
Project Management
Others
Design Thinking
MBA
Artificial Intelligence
Public Policy
PGDM
Healthcare
Technology
CXO
Management
Data Science
Data Science
Data Analytics
Skills you'll gain:
Strategic Thinking & Planning
Competitive Advantage & Market Positioning
Strategic Leadership & Decision-Making
Change Management & Organizational Transformation
Duration:
1 Year
IIM Kozhikode
IIMK Advanced Strategic Management Programme
Starts on
Mar 30, 2024
Get Details
Skills you'll gain:
Critical Thinking & Decision-Making Skills
Power of Emerging Technologies
Innovation and Drive Organizational Change
Fostering a Culture of Innovation
Duration:
9 Months
MIT xPRO
MIT Technology Leadership and Innovation
Starts on
May 14, 2024
Get Details
Skills you'll gain:
Duration:
18 Weeks
109820388
Strategic Marketing for Leaders: Leveraging AI for Growth
Starts on
undefined
Get Details
Skills you'll gain:
Opportunities & Outlining Plans to use AI & ML
Applying Data-Driven Business Innovation Best Practices
Changing Culture to Integrate AI-Enabled Technologies
Ethics, Privacy and Regulations in AI & ML
Duration:
20 Weeks
Indian School of Business
ISB Leadership in AI
Starts on
May 14, 2024
Get Details
Skills you'll gain:
Duration:
10 Months
IIM Kozhikode
CERT-IIMK-Women Leadership Programme INDIA
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
22 Weeks
Indian School of Business
SEPO - ISB Venture Capital & Private Equity India
Starts on
undefined
Get Details
Skills you'll gain:
Financial Accounting & Analysis
Financial Instruments & Markets
Corporate Finance & Valuation
Investment Management & Banking
Duration:
12 Months
IIM Kozhikode
IIMK Professional Certificate in Financial Analysis and Financial Management
Starts on
Mar 30, 2024
Get Details
Skills you'll gain:
Duration:
11 Months
IIM Lucknow
CERT-IIML SLP India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
12 Months
IIM Kozhikode
Senior Management Programme
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
10 Months
IIM Indore
Executive Programme in Business Management
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
12 Months
IIM Kozhikode
Advanced Strategic Management Programme
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
12 Weeks
IIM Kozhikode
CERT-IIMK EPIS Async India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
12 Months
IIM Kozhikode
SEPO - IIMK CEO Programme India
Starts on
undefined
Get Details
As part of the fund raise, approximately Rs 290 crore was allocated for repaying the loan obtained from
Värde Partners
in April 2022. The remaining Rs 160 crore was dedicated to the development of projects.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Struggling With Belly Fat? Try This at Home
Home Fitness Hack
Shop Now
Undo
The current funding is
growth capital
for Omaxe's ongoing projects across key markets such as
New Chandigarh
, Lucknow, Ludhiana, and
Faridabad
, along with flagship developments like
Omaxe
State in Dwarka, the upcoming
integrated township in Amritsar
, and a new township project in Indore.
'This fund infusion enables us to move faster on construction, reduce market dependence, and strategically invest in new opportunities that align with our core markets,' said Mohit Goel, Managing Director, Omaxe Ltd.
Live Events
In the last two financial years, Omaxe has repaid net Rs 1285 crore to lenders as principal payment, reducing overall net debt to Rs 300 crore. The company sold properties over Rs 3000 crore in FY25.
'With no immediate liability to repay, most of the funds would be used for faster execution and create additional headroom to explore expansion in select markets,' said Atul Banshal, Director – Finance, Omaxe Ltd.
Omaxe has delivered over 140.17 million sq. ft. of real estate and construction contracting projects to date as of March 31, 2025, with presence in 8 states and 31 cities.
Its portfolio includes integrated townships, group housing, shopping malls, office spaces, and infrastructure-led developments, with a focus on timely delivery and long-term value creation for customers and investors alike.
Recently, Omaxe acquired 450-acre land in Indore to develop an integrated township with an investment of Rs 1,200 crore.
The company is expected to generate Rs 2,500 crore in revenue over the next three years.
Earlier, the company had said that it is investing Rs 1,000 crore in developing a township in Amritsar, Punjab.
Omaxe has acquired 260 acres of land for this township, and in the first phase, it is developing 127 acres.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
a few seconds ago
- India.com
RICH Alliance: Trump's Tariff War Backfires? Russia Backs India And Hints At Emerging Ties With China
While U.S. President Donald Trump has reportedly stated that he will "substantially" increase tariffs on India, New Delhi has made it clear that it will not yield to pressure. Meanwhile, Russia has also pushed back against Washington's move. Former U.S. Secretary of State Henry Kissinger once famously said, 'Being America's enemy may be dangerous, but being its friend is fatal.' That sentiment seems to be playing out in real time as the relationship between India and the US may be emerging into a diplomatic turning point. In today's DNA episode, Managing Editor of Zee News, Rahul Sinha, analysed a possible alliance between India, Russia, and China: Watch Full DNA Episode Here: #DNAWithRahulSinha | वर्ल्ड ऑर्डर बदला.. यूएस का 'दबदबा' गया! 'मिशन RICH'..ट्रंप के लिए कितना घातक?#DNA #India #USA #DonaldTrump #TarrifWar@RahulSinhaTV — Zee News (@ZeeNews) August 5, 2025 In a strong statement, Russian Foreign Ministry spokesperson Maria Zakharova accused the U.S. of using tariffs as a tool to dominate other nations. She said countries that chose a different path from Washington were being economically pressured and that Russia supports a multipolar and equitable world order. This, she added, is why Russia stands with India—and even with China—against America's hegemonic approach. Zakharova further claimed the U.S. is reacting out of frustration as it struggles to accept its diminishing influence in the new world order. According to her, tariffs and sanctions will not stop the shift toward a new global structure. Zakharova also suggested, a new alliance could be on the brink after the US' tariffs announcement. This emerging alignment between Russia, India, and China could reshape the global balance of power. The question now being asked: Has Donald Trump's aggressive trade policy inadvertently triggered the rise of a powerful R-I-C-H bloc? What Is 'RICH'? A new alliance named 'RICH'—short for Russia, India, and China—could pose an even greater challenge to the United States than the BRICS. The acronym itself, symbolizing 'wealth and prosperity,' hints at a formidable coalition. While Russia has previously called for stronger India-Russia-China cooperation, current global tensions and Trump's policies may make this partnership more realistic than ever before. 'RICH' vs America GDP Power: America has a GDP of US Donald 28 trillion (Rs. 23 lakh crore), but the combined GDP of Russia, India, and China is close behind at Rs. 21 lakh crore. Population Power: Together, India, China, and Russia are home to nearly 3 billion people—about 37 percent of the world's population—far surpassing the U.S., which has just 330 million people or 4 percent of the global total. Military Strength: The combined military strength of the three nations is 4.8 million troops, compared to America's 1.3 million. Even when factoring in NATO allies, the numbers still tilt heavily toward the RICH bloc. Nuclear Arsenal: RICH nations possess approximately 6,300 nuclear weapons, compared to America's 5,200. Defense Capabilities, Self-Sufficiency While the U.S. remains the world's largest arms producer, Russia and China also rank among the top global arms manufacturers. India, too, is rapidly advancing toward self-reliance in defense production. Together, the three countries could pose a significant challenge to NATO on land, at sea, and in the air. However, experts caution that military confrontation between global powers could have catastrophic consequences, making economic and diplomatic battles more likely. Notably, these countries are also resource-rich and largely self-sufficient: Energy: Russia holds vast reserves of oil, gas, and coal and is a major exporter of fossil fuels. India is advancing in nuclear and solar energy, while China leads globally in the manufacture of solar panels and wind turbines. Natural Resources: Russia has significant reserves of titanium, nickel, cobalt, and uranium. China accounts for over 60 percent of global rare earth metal production. India, meanwhile, is rich in bauxite, iron ore, graphite, and manganese. Agriculture: India is the world's largest producer of milk and pulses. Russia leads in wheat exports, while China excels in agricultural machinery and food production. In short, if united, these three nations would have little need for external support in energy, food, or defense. Strategic Shifts and Diplomatic Openings While deep mistrust exists between India and China, recent developments suggest that the gap may be narrowing. India's National Security Advisor (NSA) Ajit Doval is set to visit China this month, followed by a trip by External Affairs Minister (EAM) S. Jaishankar. These diplomatic engagements, possibly accelerated by Trump's confrontational tactics, may help bridge long-standing divides.
&w=3840&q=100)
Business Standard
a few seconds ago
- Business Standard
US slams use of AI to personalise airline ticket prices, would investigate
US Transportation Secretary Sean Duffy said Tuesday the department has concerns about the use of AI to set personalised airline ticket prices and will investigate if anyone does so. Last week, Delta Air Lines told lawmakers it will not and has not used AI to set prices for individual consumers. "To try to individualise pricing on seats based on how much you make or don't make or who you are, I can guarantee you that we will investigate if anyone does that," Duffy said. "We would engage very strongly if any company tries to use AI to individually price their seating." Duffy noted Delta clarified that it would not use AI for pricing individual tickets, "and I'll take them at face value." Late last month, Democratic Senators Ruben Gallego, Mark Warner and Richard Blumenthal said they believed the Atlanta-based airline would use AI to set individual prices, which would "likely mean fare price increases up to each individual consumer's personal 'pain point.'" Delta previously said it plans to deploy AI-based revenue management technology across 20 per cent of its domestic network by the end of 2025 in partnership with Fetcherr, an AI pricing company. Fetcherr on its website says its technology is "trusted by the world's leading airlines," and lists Delta, Westjet, Virgin Atlantic, Viva and Azul. American Airlines CEO Robert Isom said last month using AI to set ticket prices could hurt consumer trust. Democratic lawmakers Greg Casar and Rashida Tlaib have introduced legislation to bar companies from using AI to set prices or wages based on Americans' personal data and would specifically ban airlines raising individual prices after seeing a search for a family obituary. Delta said airlines have used dynamic pricing for more than three decades, in which pricing fluctuates based on a variety of factors like overall customer demand, fuel prices and competition, but not a specific consumer's personal information.
&w=3840&q=100)
Business Standard
a few seconds ago
- Business Standard
Gland Pharma Q1 profit jumps 50% on core growth, Cenexi turnaround
Hyderabad-based Gland Pharma reported a 50 per cent increase in its consolidated net profit year-on-year (Y-o-Y), reaching ₹215 crore for the first quarter of the financial year (Q1FY26). Revenue from operations rose 7 per cent Y-o-Y to ₹1,505 crore. The growth was driven by robust performance in its core business and a successful turnaround at Cenexi, a French pharmaceutical contract development and manufacturing organisation (CDMO) specialising in sterile injectable and lyophilised drug products, which Gland Pharma acquired in 2023. Sequentially, the company's net profit rose by 15 per cent, and revenue increased by 6 per cent. 'We're off to a positive start this year with growth in revenue and a jump in profitability. Our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships,' said Srinivas Sadu, executive chairman, Gland Pharma. 'By enhancing our base business, investing in differentiated products and driving operational efficiencies, we are positioning ourselves for sustained growth. Our focus on adherence to global quality standards and investment in capability building position us to scale further, tap new markets and deliver long-term value,' said Shyamakant Giri, chief executive officer, Gland Pharma. During the quarter, research and development (R&D) expenses stood at ₹46 crore, accounting for 4.4 per cent of revenue. The company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin (three new strengths), Liraglutide and Acetaminophen bags. One abbreviated new drug application (ANDA) was filed and nine were approved during the quarter, bringing cumulative US ANDA filings to 372 (325 approved and 47 pending). Its in-house complex pipeline saw six product launches, with three more awaiting approval. Complex injectables remain a key driver of long-term growth, with more products being added to the pipeline. Fifteen products are in co-development (seven under the 505(b)(2) pathway and eight ANDAs), with commercialisation expected to begin in FY28. One ready-to-use (RTU) infusion bag was filed this quarter, bringing the total RTU product filings in the US to 20 (14 approved). Another 10 are in development, targeting a $767 million market. The company expanded its GLP-1 portfolio, launching Liraglutide in the UK and Australia, and is increasing GLP-1/pen/cartridge capacity from 40 million to 140 million units. It also received a good manufacturing practice (GMP) compliance certificate from the Danish Medicines Agency for aseptically prepared powder for injection, infusion and inhalation. The results were announced after market hours. Gland Pharma's stock fell by 0.95 per cent, ending the day's trade at ₹1,962.30 per share on the BSE.
